Table 4.
Most common maintenance doses and dose frequencies by treatment for first‐, second‐ and third‐line therapies; doses in patients with psoriasis initiating new therapy during the registry
| Ustekinumab | Infliximab | Adalimumab | Etanercept | |
|---|---|---|---|---|
| First‐line therapy, N | 1412 | 270 | 1274 | 1002 |
| Dose | 45 mga | 5 mg/kg | 40 mg | 50 mg |
| Frequency | Every 12 weeks | Every 8 weeksb | Every other week | Weeklyc |
| n (%) | 812 (57.5) | 120 (44.4) | 1031 (80.9) | 580 (57.9) |
| Second‐line therapy, N | 2081 | 281 | 2113 | 397 |
| Dose | 45 mga | 5 mg/kg | 40 mg | 50 mg |
| Frequency | Every 12 weeks | Every 8 weeksb | Every other week | Weeklyc |
| n (%) | 956 (45.9) | 104 (37.0) | 1743 (82.5) | 195 (49.1) |
| Third‐line therapy, N | 2040 | 358 | 621 | 177 |
| Dose | 45 mga | 5 mg/kg | 40 mg | 50 mg |
| Frequency | Every 12 weeks | Every 8 weeksb | Every other week | Twice Weeklyc |
| n (%) | 803 (39.4) | 115 (32.1) | 487 (78.4) | 92 (52.0) |
Data are reported as number of doses administered (%). N = total number of administrations for each line of therapy.
In addition, a large proportion of 90‐mg doses of ustekinumab every 12 weeks were administered, including 375/1412 (26.6%) during first‐line therapy, 733/2081 (35.2%) during second‐line therapy and 780/2040 (38.2%) during third‐line therapy.
Infliximab 5 mg/kg was administered every 6 weeks (35/270 [13.0%]) and at ‘other’ dosing intervals (32/270 (11.9%) during first‐line therapy; corresponding frequencies were 41/281 (14.6%) and 48/281 (17.1%) during second‐line therapy and 55/358 (15.4%) and 62/358 (17.3%) during third‐line therapy.
A large proportion of etanercept 50‐mg doses were administered twice weekly during first‐line therapy [375/1002 (37.4%)] and second‐line therapy [170/397 (42.8%)] and weekly during third‐line therapy (76/177 [42.9%]).